Goldfinch Bio Appoints Nephrologist Louis Brenner, M.D., M.B.A. to Board of Directors
Cambridge, Mass., February 9, 2017 – Goldfinch Bio, a company focused on discovering and developing precision therapies to treat patients with kidney disease, today announced the appointment of Louis Brenner, M.D., M.B.A. to its Board of Directors. Dr. Brenner joins interim chief executive officer Abbie Celniker, Ph.D., and interim chief operating officer Neil Exter on the Board of Goldfinch, which was launched in December 2016.
“Lou is a distinguished nephrologist with significant experience designing, planning and directing successful clinical trials in kidney disease and other areas,” said Abbie Celniker, Ph.D., Goldfinch’s interim CEO and partner at Third Rock Ventures. “We are thrilled to add him to our Board and look forward to drawing on his knowledge as we work to advance precision therapies for patients with kidney disease.”
Dr. Brenner is the chief operating officer of Allena Pharmaceuticals. He has more than a decade of industry leadership experience, including pharmaceutical development strategy, regulatory affairs, business development and marketing. His drug development successes include managing the late-stage development and regulatory submission for Feraheme® (ferumoxytol) injection in patients with chronic kidney disease (CKD) at AMAG Pharma; leading the conduct of the global Phase 3 program of a novel candidate for the treatment of osteoporosis at Radius Health; and directing global commercial planning for Renvela® (sevelamer carbonate) in patients with end stage renal disease at Genzyme. Dr. Brenner earned a B.S. from Yale University, an M.D. from Duke University and an M.B.A. from Harvard Business School. He completed his residency in internal medicine at Brigham and Women’s Hospital (BWH) and his fellowship in nephrology at BWH and Massachusetts General Hospital. Dr. Brenner currently holds a clinical appointment at BWH and was formerly a board member at PLC Medical Systems and Chairman of the Board of the National Kidney Foundation’s New England subsidiary.
“I am thrilled to support Goldfinch in its efforts to develop innovative therapies that target the molecular drivers of kidney disease,” Dr. Brenner said. “Kidney disease is an area of great unmet need, with few adequate treatment options available for patients. By integrating the most exciting breakthrough insights in kidney genetics and biology, Goldfinch is uniquely positioned to develop transformative medicines with the potential to improve patients’ lives.”
About Goldfinch Bio
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.
Dan Quinn, Ten Bridge Communications